Gabapentin Capsule
Product Images NDC 71610-185

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 185 mg (71610 0185 30)

Label for Gabapentin USP capsules shows 300 mg strength with a count of 30 capsules. The label includes storage instructions to keep between 20-25 degrees Celsius, dispensing directions, and child safety warnings. Manufacturer is Invagen Pharmaceuticals Inc., Hauppauge, NY, with repackaging by Aphena Pharma Solutions in Cookeville, TN. The product is marked for prescription use only with NDC #71610-0185-30 visible.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Gabapentin Capsules Fig01)

A line graph depicting mean pain scores over an 8-week period comparing placebo and 3600 mg/day Gabapentin. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration and a 4-week fixed dose period. The y-axis shows pain scores from 0 to 10. The graph shows pain scores decreasing more with Gabapentin than placebo over time.*

FDA Label Image

Figure 2 (Gabapentin Capsules Fig02)

A line graph depicting mean pain scores over 7 weeks for placebo and gabapentin doses of 1800 mg/day and 2400 mg/day. The x-axis shows time in weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Both gabapentin groups demonstrate a decrease in pain scores from baseline compared to placebo.*

FDA Label Image

Figure 3 (Gabapentin Capsules Fig03)

A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' compares response rates in two studies. Study 1 shows 12% for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance annotations are noted with p-values below 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentin Capsules Fig04)

A scatter plot chart displaying the percentage difference relative to daily dose (mg) for three studies labeled a, b, and c. The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis shows difference (%) from 2 to 22. Data points for each study are shown with distinct shading: study a (black squares), study b (gray squares), and study c (white squares), with varying values for each dose. The chart compares differences across studies at various doses.*

FDA Label Image

Formula (Gabapentin Capsules Formula)

A formula for creatinine clearance (CLCr) calculation shown as an equation involving age, weight, serum creatinine, and a factor for female patients. The formula uses these variables to estimate kidney function.*

FDA Label Image

Structural Formula (Gabapentin Capsules Str)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to a side chain with amino (CH2NH2) and carboxylic acid (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.